DK3296317T3 - Topk-peptider og vacciner, der indbefatter disse - Google Patents

Topk-peptider og vacciner, der indbefatter disse Download PDF

Info

Publication number
DK3296317T3
DK3296317T3 DK17198358.8T DK17198358T DK3296317T3 DK 3296317 T3 DK3296317 T3 DK 3296317T3 DK 17198358 T DK17198358 T DK 17198358T DK 3296317 T3 DK3296317 T3 DK 3296317T3
Authority
DK
Denmark
Prior art keywords
vaccines including
peptides
top peptides
vaccines
Prior art date
Application number
DK17198358.8T
Other languages
English (en)
Inventor
Yusuke Nakamura
Ryuji Osawa
Tomohisa Watanabe
Gaku Nakayama
Takuya Tsunoda
Sachiko Yoshimura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DK3296317T3 publication Critical patent/DK3296317T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/12—Dual-specificity kinases (2.7.12)
    • C12Y207/12002—Mitogen-activated protein kinase kinase (2.7.12.2), i.e. MAPKK or MEK1 or MEK2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK17198358.8T 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse DK3296317T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161552817P 2011-10-28 2011-10-28
EP12844519.4A EP2771350B1 (en) 2011-10-28 2012-10-25 Topk peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
DK3296317T3 true DK3296317T3 (da) 2020-02-24

Family

ID=48167445

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17198358.8T DK3296317T3 (da) 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse
DK12844519.4T DK2771350T3 (da) 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12844519.4T DK2771350T3 (da) 2011-10-28 2012-10-25 Topk-peptider og vacciner, der indbefatter disse

Country Status (19)

Country Link
US (2) US9427461B2 (da)
EP (2) EP3296317B1 (da)
JP (2) JP6124149B2 (da)
KR (2) KR102020491B1 (da)
CN (2) CN104066746B (da)
AU (2) AU2012329502B2 (da)
BR (2) BR112014009176B1 (da)
CA (2) CA2852633C (da)
DK (2) DK3296317T3 (da)
ES (2) ES2665576T3 (da)
HK (2) HK1201542A1 (da)
IL (2) IL231583B (da)
IN (1) IN2014CN03922A (da)
MX (1) MX355759B (da)
RU (1) RU2633503C2 (da)
SG (3) SG10201913173SA (da)
TW (2) TWI617582B (da)
UA (1) UA114298C2 (da)
WO (1) WO2013061594A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017150084A1 (ja) * 2016-02-29 2017-09-08 京セラドキュメントソリューションズ株式会社 電子機器およびマーカー処理方法
US11325959B2 (en) 2017-01-25 2022-05-10 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
WO2019178081A1 (en) * 2018-03-12 2019-09-19 The Children's Hospital Of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
WO2022066973A1 (en) * 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022109258A1 (en) * 2020-11-19 2022-05-27 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class i peptides
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
ID27788A (id) 1998-06-25 2001-04-26 Kyogo Itoh Cs Peptida-peptida antigen tumor yang diperoleh dari siklofilin b
AU2001296448A1 (en) 2000-10-03 2002-04-15 Curagen Corporation Tumor marker and methods of use
JP4608184B2 (ja) 2001-03-14 2011-01-05 ダコ デンマーク アクティーゼルスカブ 新規なｍｈｃ分子構築物、ならびに診断および処置のためにこれらの構築物を用いる方法、ならびにｍｈｃ分子の使用
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
JP4579246B2 (ja) * 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
EP1907581A2 (en) 2005-07-27 2008-04-09 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
PT1910839T (pt) * 2005-07-27 2016-07-14 Oncotherapy Science Inc Gene tom34 relacionado com o cancro do cólon
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
KR20090064378A (ko) * 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 유방암 관련 유전자 및 폴리펩티드
US20090081659A1 (en) * 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
AU2008332278C1 (en) * 2007-12-05 2013-10-03 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
WO2010023854A1 (en) 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Cancer related gene, lgn/gpsm2
US20120107333A1 (en) 2009-03-04 2012-05-03 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer

Also Published As

Publication number Publication date
EP2771350A1 (en) 2014-09-03
JP6124149B2 (ja) 2017-05-10
JP2017093442A (ja) 2017-06-01
BR112014009176A2 (pt) 2020-10-27
ES2665576T3 (es) 2018-04-26
SG2014012363A (en) 2014-09-26
US20140255437A1 (en) 2014-09-11
IN2014CN03922A (da) 2015-09-04
HK1251236A1 (zh) 2019-01-25
KR102127211B1 (ko) 2020-06-29
MX2014004875A (es) 2014-09-22
EP3296317B1 (en) 2019-12-11
AU2017200530A1 (en) 2017-02-23
US20160310586A1 (en) 2016-10-27
SG10201913173SA (en) 2020-03-30
US9849166B2 (en) 2017-12-26
KR20190107156A (ko) 2019-09-18
IL245924B (en) 2019-03-31
CA3122778A1 (en) 2013-05-02
HK1201542A1 (en) 2015-09-04
TW201333044A (zh) 2013-08-16
IL231583B (en) 2019-02-28
BR122021015246B1 (pt) 2023-03-28
JP2014533095A (ja) 2014-12-11
CN107759661A (zh) 2018-03-06
CA2852633A1 (en) 2013-05-02
EP2771350A4 (en) 2015-07-15
TW201716429A (zh) 2017-05-16
ES2773699T3 (es) 2020-07-14
IL231583A0 (en) 2014-05-28
CA2852633C (en) 2021-08-03
CN107759661B (zh) 2021-03-23
JP6349560B2 (ja) 2018-07-04
KR102020491B1 (ko) 2019-09-10
TWI617582B (zh) 2018-03-11
AU2012329502B2 (en) 2016-11-24
US9427461B2 (en) 2016-08-30
EP3296317A1 (en) 2018-03-21
MX355759B (es) 2018-04-27
EP2771350B1 (en) 2018-01-10
IL245924A0 (en) 2016-07-31
CN104066746B (zh) 2017-12-05
RU2014121502A (ru) 2015-12-10
RU2633503C2 (ru) 2017-10-12
TWI681973B (zh) 2020-01-11
BR112014009176B1 (pt) 2022-08-30
WO2013061594A1 (en) 2013-05-02
KR20140085565A (ko) 2014-07-07
UA114298C2 (uk) 2017-05-25
AU2017200530B2 (en) 2018-08-09
AU2012329502A1 (en) 2014-05-29
SG10201608552WA (en) 2016-12-29
DK2771350T3 (da) 2018-04-30
CN104066746A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK3130347T3 (da) PH20-polypeptidvarianter, formuleringer og anvendelser deraf
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
CO7020851A2 (es) Proteínas y péptidos modificados
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK2699397T3 (da) Apparater, system og fremgangsmåder til at danne pressede artikler og pressede artikler dannet derved
DK2850202T3 (da) Fremgangsmåder og grupper
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK2950535T3 (da) Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand
CO7020866A2 (es) Péptidos terapéuticos
BR112014004902A2 (pt) peptídeos
DK2552434T3 (da) Peptider og anvendelse deraf
DK2729160T3 (da) Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK2812356T3 (da) CDIM-bindende proteiner og anvendelser deraf
CO6870003A2 (es) Vacunas bovinas y métodos
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
DK3232663T3 (da) Fremgangsmåder og anordninger til afkodning
BR112013017488A2 (pt) peptídeos imunogênicos multiméricos e monoméricos